Peptide Schedule
Dermorphin7 residuesYAFGYPSEach bubble = one amino acid. Size = residue mass. Color = chemical class.Dermorphin
Benefits
About Dermorphin
Dermorphin is a naturally occurring heptapeptide (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first isolated in 1981 from the skin secretions of South American tree frogs of the genus Phyllomedusa, particularly Phyllomedusa sauvagei and Phyllomedusa bicolor. It is one of the most potent naturally occurring opioid peptides known, exhibiting 30-40 times greater analgesic potency than morphine and binding mu-opioid receptors with a Ki of approximately 0.2-0.5 nM. The presence of a D-alanine residue at position 2 — a rare feature in vertebrate peptides — confers resistance to enzymatic degradation and restricts the peptide backbone into a conformation optimal for mu-receptor activation. The D-Ala2 residue is biosynthesized from L-alanine in the precursor protein through a post-translational isomerization unique to amphibian skin peptides. In preclinical studies, dermorphin administered intrathecally was 3,000-5,000 times more active than spinal morphine in standard nociceptive assays. When injected intracerebroventricularly in rodents, it produced potent dose-dependent analgesia reversed by naloxone, confirming opioid receptor-mediated activity. Interestingly, dermorphin appears to induce slower tolerance development and less intense naloxone-precipitated withdrawal compared to morphine, which initially generated interest for potential clinical applications. A 2018 review explored its possible role in intrathecal palliative care for oncological pain, though this remains entirely theoretical. Despite these properties, dermorphin has never been approved for human clinical use in any jurisdiction. Its primary notoriety comes from illicit use in horse racing. Dermorphin was undetectable by standard equine drug screens until 2011, when intelligence from North American tracks led to the development of LC-MS/MS detection methods. Approximately 30 positive cases were identified in Oklahoma and Louisiana, triggering industry-wide regulatory action. WARNING: Dermorphin is a potent opioid agonist with high abuse and addiction potential. It produces respiratory depression, physical dependence, and can be lethal in overdose. It is classified as a controlled or banned substance in multiple jurisdictions worldwide.
Who Should Consider Dermorphin
- Opioid receptor pharmacology researchers
- Neuroscience and pain signaling investigators
- Analytical chemists developing equine drug detection methods
- Medicinal chemists studying structure-activity relationships of opioid peptides
How Dermorphin Works
Dermorphin exerts its effects primarily through high-affinity agonism at the mu-opioid receptor (MOR). The peptide binds MOR with a dissociation constant (Kd) of approximately 0.46 nM, as determined by equilibrium binding studies using tritiated dermorphin in rat brain membranes. Upon binding, dermorphin activates Gi/Go protein coupling, which triggers three downstream signaling cascades: inhibition of adenylyl cyclase leading to reduced intracellular cAMP levels, closure of voltage-gated N-type calcium channels reducing neurotransmitter release, and opening of inwardly rectifying potassium channels (GIRKs) causing neuronal hyperpolarization. The net result is suppression of nociceptive signal transmission at both spinal and supraspinal levels. Structurally, the N-terminal tetrapeptide sequence Tyr-D-Ala-Phe-Gly constitutes the pharmacophoric "message" domain responsible for opioid receptor activation, while the C-terminal tripeptide Tyr-Pro-Ser-NH2 serves as the "address" domain that directs selectivity toward mu-receptors over delta and kappa subtypes. Dermorphin also promotes MOR internalization via beta-arrestin recruitment, and blocking this internalization attenuates the antinociceptive response, indicating that receptor trafficking is an active component of the signaling mechanism rather than merely a desensitization pathway. At the systems level, dermorphin modulates descending pain inhibitory pathways originating in the periaqueductal gray and rostral ventromedial medulla, amplifying endogenous pain suppression circuits.
What to Expect
Rapid onset of analgesia in preclinical models. Peak plasma concentration reached almost immediately after IV administration. Profound mu-opioid receptor activation with measurable antinociceptive response in rodent hot-plate and tail-flick assays.
Sustained analgesic effect despite rapid plasma clearance (t1/2 ~1.3 min), suggesting tissue-level receptor binding persists beyond plasma availability. Respiratory rate depression observed in animal models.
Gradual waning of analgesic effect after single-dose administration. Duration of action is longer than plasma half-life due to slow receptor dissociation kinetics and receptor internalization dynamics.
Return to baseline nociceptive thresholds after single dose. Complete metabolic clearance from plasma via hepatic and renal peptidase activity.
Measurable analgesic tolerance develops with repeated administration in animal models, though onset is slower than with equivalent morphine protocols. Signs of physical dependence may emerge.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | Single dose |
| Moderate | 100mcg | Single dose |
| Aggressive | 200mcg | Single dose |
Note: Dermorphin is a Schedule-restricted mu-opioid agonist peptide with 30-40x the potency of morphine. It is banned by the Association of Racing Commissioners International (ARCI) as a Class I substance in equine competition and has been at the center of multiple horse racing doping scandals since 2011. This peptide carries high abuse and dependence potential. In many jurisdictions it is treated as a controlled substance or regulated analog of morphine. It is presented here strictly for academic and research reference. Dermorphin is NOT appropriate for self-administration, performance enhancement, or recreational use. Researchers should verify local regulations before procurement.
How to Inject Dermorphin
FOR RESEARCH USE ONLY. Dermorphin is reconstituted by adding bacteriostatic water to the lyophilized vial — gently swirl until fully dissolved, do not vortex. In preclinical research, routes of administration have included subcutaneous, intravenous, intrathecal, and intracerebroventricular injection. Subcutaneous and IV are the most common peripheral routes studied. Doses in animal models range from low nanogram to low microgram quantities depending on species and route. All handling should follow institutional opioid safety protocols including locked storage, usage logs, and waste disposal procedures consistent with controlled substance regulations. Emergency opioid reversal agents (naloxone) must be immediately accessible whenever dermorphin is being used in any experimental setting.
Cycling Protocol
DEPENDENCE WARNING: Dermorphin should not be used in repeated dosing protocols outside of strictly controlled research settings. Even short-duration repeated exposure carries risk of physical dependence and opioid withdrawal. There is no established or recommended cycling protocol for human use. Any investigational protocol must include naloxone availability and medical supervision. Tolerance to analgesic effects can develop within days of repeated administration.
Pharmacokinetics
Source: Plasma t1/2 ~1.3 min; terminal elimination t1/2 ~45 min IV in horses (Robinson et al., 2015, PMID 25376170)
Loading the interactive decay curve.
Side Effects
Dermorphin carries the full spectrum of mu-opioid agonist side effects, amplified by its extreme potency. Respiratory depression is the primary lethal risk — bolus injection can induce apnea in animal models. Other opioid-typical effects include profound sedation, nausea and vomiting, constipation and reduced gastrointestinal motility, miosis (pupil constriction), bradycardia, and urinary retention. Physical dependence develops with repeated administration, and abrupt cessation produces opioid withdrawal symptoms including agitation, muscle pain, insomnia, diarrhea, and autonomic instability, though preclinical data suggest these may be less intense than morphine withdrawal at equivalent analgesic doses. Tolerance to the analgesic effect develops with chronic use, leading to dose escalation. ADDICTION WARNING: As a potent mu-opioid agonist, dermorphin carries high psychological and physical addiction potential. Individuals with a history of substance use disorder are at extreme risk. Overdose can be fatal, particularly when combined with other CNS depressants. Naloxone should be available as an emergency reversal agent in any research setting where dermorphin is handled.
Contraindications
- Pregnancy and breastfeeding — opioid peptides cross the placental barrier
- History of substance use disorder or opioid addiction
- Respiratory insufficiency or compromised airway, including sleep apnea
- Severe hepatic impairment (reduced peptidase metabolism)
- Concurrent use of MAO inhibitors
- Known hypersensitivity to dermorphin or amphibian-derived peptides
- Paralytic ileus or gastrointestinal obstruction
- Unmonitored settings without access to naloxone reversal
- Pediatric populations (no safety data)
- Traumatic brain injury with elevated intracranial pressure
Drug Interactions
- Benzodiazepines — severe additive CNS and respiratory depression; potentially fatal combination
- Other opioid agonists (morphine, fentanyl, oxycodone) — additive respiratory depression and overdose risk
- Alcohol — potentiates sedation and respiratory depression
- CNS depressants including barbiturates, sedative antihistamines, and general anesthetics
- MAO inhibitors — risk of serotonin syndrome and unpredictable potentiation of opioid effects
- Muscle relaxants (baclofen, cyclobenzaprine) — enhanced sedation
- Naloxone and naltrexone — opioid receptor antagonists that reverse dermorphin effects; naloxone required as emergency reversal agent
- Gabapentinoids (gabapentin, pregabalin) — increased risk of respiratory depression when combined with opioids
Storage & Stability
Molecular Profile
Related Peptides
References
- Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skinPubMed 7195758
- Characterisation and visualisation of [3H]dermorphin binding to mu opioid receptors in the rat brainPubMed 2161761
- Spinal action of dermorphin, an extremely potent opioid peptide from frog skinPubMed 2877713
- Opioid receptor internalization contributes to dermorphin-mediated antinociceptionPubMed 22351775
- Pharmacokinetics and pharmacodynamics of dermorphin in the horsePubMed 25376170
- Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliationPubMed 30203008
- Detection, quantification, and identification of dermorphin in equine plasma and urine by LC-MS/MS for doping controlPubMed 23571464
- D-alanine in the frog skin peptide dermorphin is derived from L-alanine in the precursorPubMed 3659910
- Opioid peptides from frog skinPubMed 9949868
- Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood-brain barrier penetrationPubMed 9723966